Brewin Dolphin Wealth Management’s Takeda Pharmaceutical TAK Stock Holding History

Brewin Dolphin Wealth Management’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$4K	Sell	300 -448	-60%	-$6.39K	﹤0.01%	313
2022 Q1	$11K	Buy	748 +448	+149%	+$6.58K	﹤0.01%	285
2021 Q4	$4K	Hold	300	–	–	﹤0.01%	308
2021 Q3	$4.91K	Hold	300	–	–	﹤0.01%	312
2021 Q2	$5.05K	Hold	300	–	–	﹤0.01%	313
2021 Q1	$5.48K	Hold	300	–	–	﹤0.01%	301
2020 Q4	$5.46K	Hold	300	–	–	﹤0.01%	261
2020 Q3	$5.35K	Hold	300	–	–	﹤0.01%	256
2020 Q2	$5.38K	Hold	300	–	–	﹤0.01%	264
2020 Q1	$4.55K	Buy	+300	New	+$5.44K	﹤0.01%	185

Other funds holding TAK

MIP

Mondrian Investment Partners London, United Kingdom $6.69B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Brewin Dolphin Wealth Management's TAK Position: Q2 2022 in Review

Brewin Dolphin Wealth Management reduced its Takeda Pharmaceutical (TAK) stake by 60% in Q2 2022, selling an estimated $6.39K and leaving 300 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #313.

Brewin Dolphin Wealth Management first reported a position in TAK in Q1 2020 and has held it in 10 quarters since. The position peaked at $11K in Q1 2022. 282 funds tracked by Wall St. Rank hold TAK as of Q2 2022.

Brewin Dolphin Wealth Management held 300 shares of Takeda Pharmaceutical worth $4K as of Q2 2022.
Brewin Dolphin Wealth Management sold 448 Takeda Pharmaceutical shares in Q2 2022, an estimated $6.39K.
Takeda Pharmaceutical made up ﹤0.01% of Brewin Dolphin Wealth Management's portfolio in Q2 2022, its #313 holding.
Brewin Dolphin Wealth Management first reported a position in Takeda Pharmaceutical in Q1 2020 and has held it in 10 quarters since.
Brewin Dolphin Wealth Management's Takeda Pharmaceutical position peaked at $11K in Q1 2022.
282 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q2 2022.

Based on Brewin Dolphin Wealth Management's 13F filing for Q2 2022, filed 14 Nov 2022.